Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Vertical gray bars indicate mitotic events, while circles mark G1/S (red) and S/G2 (blue ... (E) Violin plots showing S-phase duration (n > 400 cells/condition) (left) and G2/M-phase duration (n > 150 ...

The new demand charge will apply to the two lowest levels of energy use, the G1 and G2 customers. These are mostly residences and make up 92% of OCEC’s meters. Larger G3 and G4 customers already pay a ...

Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

Navy Yard is one of the busiest development neighborhoods in DC, with nearly 3,500 residential units in the pipeline. Below, ...

Selective protein recognition is critical in molecular biology techniques such as Western blotting and ELISA. Successful detection of the target proteins in these methods relies on the specific ...

Navy Yard is one of the busiest development neighborhoods in DC, with nearly 3,500 residential units in the pipeline. Below, ...

As shown in Figure 2A (representative histogram for numbers of CD4 T cells in G0/1, S, and G2/M phases at day 3 and summary data at day 1, 3, and 5), there were significant differences in the ...